Overview

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of SKB264 in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care

Phase:

Phase 3

Details

Lead Sponsor:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Treatments:

Capecitabine
Gemcitabine
Vinorelbine